Ren Yi, Wen Zhenghao, Zhou Suzhen, Lu Lin, Hua Zhen, Sun Yanxia
Department of Anesthesiology, Beijing Hospital, National Center of Geronotology, Insititute of Geriatric Medicine, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
Jiamusi University, Jiamusi, Heilongjiang, China.
BMJ Open. 2025 Jan 15;15(1):e086263. doi: 10.1136/bmjopen-2024-086263.
The association between preoperative blood biomarkers and major adverse cardiac events (MACEs) as well as mortality after major orthopaedic surgery remains unclear. This study aimed to assess the association between preoperative blood biomarkers and postoperative MACEs as well as all-cause mortality in patients undergoing major orthopaedic surgery.
A systematic review and meta-analysis.
PubMed, EMBASE, the Cochrane Controlled Trials Register and Cochrane Database of Systematic Reviews from inception to 20 October 2024 were searched.
Observational or experimental studies reporting the correlation between preoperative blood biomarkers and postoperative MACEs-categorised as short-term (within 3 months) or long-term (beyond 3 months)-and all-cause mortality in patients undergoing major orthopaedic surgery.
Data from studies reporting OR or HR and its 95% CI were pooled for analysis using random-effects model.
21 preoperative blood-based biomarkers from 80 studies with 226 468 patients were analysed. Elevated preoperative cardiac biomarkers were correlated with a heightened risk of MACEs within 3 months (natriuretic peptide: OR 3.37, 95% CI 2.07 to 5.47, I=87.9%; cardiac troponin: OR 4.89, 95% CI 1.52 to 15.75, I=69.5%) with significant heterogeneity. Only natriuretic peptide was associated with a high-risk long-term MACEs (>3 months) (OR 3.52, 95% CI 1.73 to 7.17, I=86.2%). In contrast, cardiac biomarkers were not identified as having prognostic value for all-cause mortality in this patient cohort. Additionally, an increased risk of all-cause mortality was associated with preoperative abnormal levels of albumin (OR 1.15, 95% CI 1.06 to 1.24, I=84.8%), creatinine (OR 1.54, 95% CI 1.12 to 1.95, I=0), 25(OH)D (OR 1.58, 95% CI 1.01 to 2.14, I=0) and glomerular filtration rate (GFR) (OR 1.12, 95% CI 1.06 to 1.17, I=0), rather than cardiac biomarkers.
The study proposed that cardiac biomarkers assessed before surgery could offer prognostic insight into short-term MACEs, while preoperative abnormal levels of albumin, creatinine, 25 (OH)D and GFR might be prognostic valuable for all-cause mortality following major orthopaedic surgery.
CRD42022352091.
术前血液生物标志物与重大骨科手术后主要不良心脏事件(MACE)及死亡率之间的关联尚不清楚。本研究旨在评估接受重大骨科手术患者术前血液生物标志物与术后MACE以及全因死亡率之间的关联。
系统评价和荟萃分析。
检索了从创刊至2024年10月20日的PubMed、EMBASE、Cochrane对照试验注册库和Cochrane系统评价数据库。
观察性或实验性研究,报告接受重大骨科手术患者术前血液生物标志物与术后MACE(分为短期(3个月内)或长期(3个月后))及全因死亡率之间的相关性。
使用随机效应模型汇总报告OR或HR及其95%CI的研究数据进行分析。
分析了来自80项研究的226468例患者的21种术前血液生物标志物。术前心脏生物标志物升高与3个月内发生MACE的风险增加相关(利钠肽:OR 3.37,95%CI 2.07至5.47,I² = 87.9%;心肌肌钙蛋白:OR 4.89,95%CI 1.52至15.75,I² = 69.5%),存在显著异质性。只有利钠肽与长期MACE(>3个月)高风险相关(OR 3.52,95%CI 1.73至7.17,I² = 86.2%)。相比之下,在该患者队列中,心脏生物标志物未被确定对全因死亡率具有预后价值。此外,术前白蛋白(OR 1.15,95%CI 1.06至1.24,I² = 84.